Skip to main content
Erschienen in: Clinical Rheumatology 1/2006

01.02.2006 | Original Article

Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients

verfasst von: Ismail Bejia, Kamel Ben Salem, Mongi Touzi, Naceur Bergaoui

Erschienen in: Clinical Rheumatology | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study was to determine the feasibility, reliability and validity of the time trade-off (TTO) in Tunisian rheumatoid arthritis (RA) patients. The TTO was used to measure the utility in 122 RA patients with increasing difficulty in performing activities of daily living. The 1-week test–retest reproducibility was studied in 57 patients using the intraclass correlation coefficient (ICC). Validity was evaluated by comparison with other outcome measures: utility rating scale (RS), quality of life (QOL) [arthritis impact measurement scale 2 (AIMS2), rheumatoid arthritis quality of life (RAQOL)], functional status [health assessment questionnaire (HAQ), Lee index] and disease activity score (DAS). Eight patients (6.6%) did not complete the TTO. The median value of the TTO score was 0.655 (0.019–1.000). The ICC for reliability of the TTO was 0.89 (p<0.001). The TTO showed poor to moderate correlation (Spearman’s correlation coefficients between 0.2 and 0.409, p<0.01) with AIMS2, RAQOL, HAQ and Lee index. We did not find any correlation between TTO and DAS. Multiple regression analysis showed that only 32% of TTO scores could be explained. The TTO method appeared to be reliable in a group of Tunisian RA patients, but TTO values were poorly to moderately related to measures of QOL, functional ability, and disease activity. We think that TTO and RS are not feasible for use in RA patients.
Literatur
1.
Zurück zum Zitat Pincus T, Callahan LF (1993) The ‘side effects’ of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 32 [Suppl 1]:28–37 Pincus T, Callahan LF (1993) The ‘side effects’ of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 32 [Suppl 1]:28–37
2.
Zurück zum Zitat Tella MN, Feinglass J, Chang RW (2003) Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002. Curr Opin Rheumatol 15:127–131CrossRefPubMed Tella MN, Feinglass J, Chang RW (2003) Cost-effectiveness, cost-utility, and cost-benefit studies in rheumatology: a review of the literature, 2001–2002. Curr Opin Rheumatol 15:127–131CrossRefPubMed
3.
Zurück zum Zitat Sampietro-Colom L, Phillips VL, Hutchinson AB (2004) Eliciting women’s preferences in health care: a review of the literature. Int J Technol Assess Health Care 20:145–155CrossRefPubMed Sampietro-Colom L, Phillips VL, Hutchinson AB (2004) Eliciting women’s preferences in health care: a review of the literature. Int J Technol Assess Health Care 20:145–155CrossRefPubMed
4.
Zurück zum Zitat Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593–603CrossRefPubMed Torrance GW (1987) Utility approach to measuring health-related quality of life. J Chronic Dis 40:593–603CrossRefPubMed
5.
Zurück zum Zitat Bejia I, Younes M, Zrour S, Bayoudh F, Touzi M, Bergaoui N (2004) Validation of the Tunisian version of the arthritis impact measurement scale 2 questionnaire (abstract). Ann Rheum Dis 63 [Suppl 1]:435 Bejia I, Younes M, Zrour S, Bayoudh F, Touzi M, Bergaoui N (2004) Validation of the Tunisian version of the arthritis impact measurement scale 2 questionnaire (abstract). Ann Rheum Dis 63 [Suppl 1]:435
6.
Zurück zum Zitat Bejia I, Zrour S, Touzi M, Bergaoui N (2003) The validation of the Tunisian version of the RAQoL questionnaire (abstract). Ann Rheum Dis 62 [Suppl 1]:433 Bejia I, Zrour S, Touzi M, Bergaoui N (2003) The validation of the Tunisian version of the RAQoL questionnaire (abstract). Ann Rheum Dis 62 [Suppl 1]:433
7.
Zurück zum Zitat Lee P, Jasani MK, Dick WC, Buchanan WW (1973) Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol 2:71–77PubMed Lee P, Jasani MK, Dick WC, Buchanan WW (1973) Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol 2:71–77PubMed
8.
Zurück zum Zitat Bejia I, Zrour S, Touzi M, Bergaoui N (2003) Validation of the Tunisian version of the health assessment questionnaire (HAQ) in rheumatoid arthritis patients (abstract). Ann Rheum Dis 62 [Suppl 1]:434 Bejia I, Zrour S, Touzi M, Bergaoui N (2003) Validation of the Tunisian version of the health assessment questionnaire (HAQ) in rheumatoid arthritis patients (abstract). Ann Rheum Dis 62 [Suppl 1]:434
9.
Zurück zum Zitat Tijhuis GJ, Jansen SJ, Stiggelbout AM, Zwinderman AH, Hazes JM, Vlieland TP (2000) Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 59:892–897PubMed Tijhuis GJ, Jansen SJ, Stiggelbout AM, Zwinderman AH, Hazes JM, Vlieland TP (2000) Value of the time trade off method for measuring utilities in patients with rheumatoid arthritis. Ann Rheum Dis 59:892–897PubMed
10.
Zurück zum Zitat Ferraz MB, Quaresma MR, Goldsmith CH, Bennett K, Atra E (1994) Estimation of benefits and risks of the treatment of rheumatoid polyarthritis with glucocorticoids using the health-related quality of life measurements. Rev Rhum Engl Ed 61:255–259 Ferraz MB, Quaresma MR, Goldsmith CH, Bennett K, Atra E (1994) Estimation of benefits and risks of the treatment of rheumatoid polyarthritis with glucocorticoids using the health-related quality of life measurements. Rev Rhum Engl Ed 61:255–259
11.
Zurück zum Zitat Katz JN, Phillips CB, Fossel AH, Liang MH (1994) Stability and responsiveness of utility measures. Med Care 32:183–188PubMed Katz JN, Phillips CB, Fossel AH, Liang MH (1994) Stability and responsiveness of utility measures. Med Care 32:183–188PubMed
12.
Zurück zum Zitat Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Habbema JDF, De Haes JCJM (1995) The utility of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 48:1207–1214 Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Habbema JDF, De Haes JCJM (1995) The utility of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidemiol 48:1207–1214
13.
Zurück zum Zitat Dobrez DG, Calhoun EA (2004) Testing subject comprehension of utility questionnaires. Qual Life Res 13:369–376CrossRefPubMed Dobrez DG, Calhoun EA (2004) Testing subject comprehension of utility questionnaires. Qual Life Res 13:369–376CrossRefPubMed
14.
Zurück zum Zitat Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5:559–575PubMed Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5:559–575PubMed
15.
Zurück zum Zitat Salaffi F, Stancati A, Carotti M (2002) Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol 21:478–487 Salaffi F, Stancati A, Carotti M (2002) Responsiveness of health status measures and utility-based methods in patients with rheumatoid arthritis. Clin Rheumatol 21:478–487
16.
Zurück zum Zitat Van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM (2004) Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making 24:511–517CrossRefPubMed Van Osch SM, Wakker PP, van den Hout WB, Stiggelbout AM (2004) Correcting biases in standard gamble and time tradeoff utilities. Med Decis Making 24:511–517CrossRefPubMed
17.
Zurück zum Zitat Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A et al (1998) Prostate cancer patients’ utilities for health states: how it looks depends on where you stand. Med Decis Making 18:278–286PubMed Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A et al (1998) Prostate cancer patients’ utilities for health states: how it looks depends on where you stand. Med Decis Making 18:278–286PubMed
18.
Zurück zum Zitat Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J (2004) Health status versus utilities of patients with end-stage liver disease. Qual Life Res 13:773–82CrossRefPubMed Bryce CL, Angus DC, Switala J, Roberts MS, Tsevat J (2004) Health status versus utilities of patients with end-stage liver disease. Qual Life Res 13:773–82CrossRefPubMed
Metadaten
Titel
Measuring utilities by the time trade-off method in Tunisian rheumatoid arthritis patients
verfasst von
Ismail Bejia
Kamel Ben Salem
Mongi Touzi
Naceur Bergaoui
Publikationsdatum
01.02.2006
Erschienen in
Clinical Rheumatology / Ausgabe 1/2006
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-1125-6

Weitere Artikel der Ausgabe 1/2006

Clinical Rheumatology 1/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.